A groundbreaking study from Denmark has revealed that weight loss injections such as semaglutide, marketed under the brand names Wegovy and Ozempic, may significantly curb alcohol consumption in individuals with alcohol use disorder. The findings offer a promising new avenue for treating addiction.
Study Details and Results
The 26-week clinical trial involved 108 obese participants diagnosed with alcohol use disorder. Half of the group received semaglutide, while the other half was given a placebo. All participants also engaged in talking therapy sessions. The results were striking: those treated with semaglutide saw their heavy drinking days plummet from an average of 17 per month to just five. Overall alcohol intake also dropped substantially.
How Semaglutide Works
Researchers believe that semaglutide, originally developed for diabetes and weight management, influences the biological mechanisms underlying addiction. It appears to act on brain pathways involved in reward and craving, potentially reducing the urge to consume alcohol. This dual benefit—tackling both obesity and addiction—could revolutionise treatment protocols.
Expert Commentary
Dr. Helena Mikkelsen, lead author of the study, noted: "These early results are encouraging and suggest that semaglutide could serve as a complementary therapy for alcohol use disorder. However, we must proceed with caution." Experts stress the need for larger, longer-term trials across diverse populations to confirm the efficacy and safety of this approach. Understanding potential side effects and optimal dosing is also critical before clinical recommendations can be made.
Alcohol use disorder remains a major public health challenge, with limited pharmacological options. If confirmed, semaglutide could offer a novel mechanism of action, distinct from existing medications. The study was published in a peer-reviewed journal and has sparked interest among addiction specialists worldwide.
